Altoida, Inc.
9 News & Press Releases found

Altoida, Inc. news

Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences:<

Oct. 31, 2022

The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and 

Jun. 15, 2022

The Women’s Brain Project, an international non-profit organization studying gender and sex determinants to brain and mental health and 

Jun. 15, 2022

Mission Based Media, a leader in podcasts about health, care and well-being, has launched a new podcast miniseries about Alzheimer`s disease.  The Alzheimer`s Podcast miniseries provides insights and information for those who are diagnosed with Alzheimer`s disease and the people who care about them.  The miniseries was created with support from Altoida, a leading platform to improve drug development, research, and care for patie

Jun. 14, 2022

Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medi

May. 31, 2022

Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for i

May. 30, 2022

Altoida, Inc. an artificial intelligence (AI) company pioneering next-generation neurological disease diagnostics, announced today a partnership with Click Therapeutics, a leader in Digital Therapeutics™ as prescription medi

Feb. 24, 2022

Altoida, Inc. an AI company pioneering next-generation neurological disease diagnostics, and GN Group, a global leader in intelligent audio solutions, have signed a multi-year strategic partnership to research and develop new digital biomarkers for identifying Mild Cognitive Impairment (MCI). The research will serve as the backbone for new augmented reality tools to help at-risk individuals gain timely and accurate health insights using GN Group’s device technologies and, ultimate

Feb. 7, 2022